Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Enasidenib in Hepatic Impairment
NCT03290443Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enasidenib in acute myeloid leukemia (AML) (4 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration at Day 1, Area Under the Curve from time zero to infinity and 2 more. Started Sep 2017; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03290443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03290443.